Literature DB >> 1534671

Approaches to management of fungal infections in cancer patients.

P Francis1, T J Walsh.   

Abstract

The patient most susceptible to invasive aspergillosis has had prolonged granulocytopenia resulting from intensive chemotherapy and/or radiation therapy, aplastic anemia, or acute leukemia. The sinuses and lungs are usually involved, but the infection may disseminate to the endocardium, skin, CNS, and eye. Efficacy of antifungal treatment with amphotericin B depends on early recognition and aggressive intervention. In severe or refractory cases, addition of flucytosine, rifampin, or fluconazole may be beneficial. The most ominous presentation of zygomycosis involves sinus and orbital destruction and necrosis. However, pulmonary involvement is the most common manifestation in cancer patients. Infections with Pseudallescheria boydii, Fusarium species, and Trichosporon beigelii are increasingly being recognized in cancer patients, as are Malassezia furfur and invasive mycoses from dematiaceous molds.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1534671

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  3 in total

1.  Monitoring spread of Malassezia infections in a neonatal intensive care unit by PCR-mediated genetic typing.

Authors:  A van Belkum; T Boekhout; R Bosboom
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

2.  Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method.

Authors:  A Gehrt; J Peter; P A Pizzo; T J Walsh
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

3.  Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis.

Authors:  Sondus Alkhazraji; Teclegiorgis Gebremariam; Abdullah Alqarihi; Yiyou Gu; Zeinab Mamouei; Shakti Singh; Nathan P Wiederhold; Karen J Shaw; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.